Fig. 7From: Long-term prophylaxis with lanadelumab for HAE: authorization for temporary use in FranceAdverse events (AEs; by Preferred Term) occurring in ≥ 5% frequency in the total population (n = 77). All AE were nonserious. HAE hereditary angioedemaBack to article page